107 related articles for article (PubMed ID: 8626270)
1. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae.
Klugman K; Wasas A
J Antimicrob Chemother; 1995 Nov; 36(5):873-4. PubMed ID: 8626270
[No Abstract] [Full Text] [Related]
2. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.
Thomson KS; Chartrand SA; Sanders CC; Block SL
Antimicrob Agents Chemother; 1997 Feb; 41(2):478-80. PubMed ID: 9021213
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo activity of trovafloxacin against Streptococcus pneumoniae.
Klugman KP; Gootz TD
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():51-5. PubMed ID: 9222070
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.
Urbásková P; Trupl J; Hupková H; Appelbaum PC; Jacobs MR
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):686-8. PubMed ID: 8894582
[TBL] [Abstract][Full Text] [Related]
5. Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden.
Liljequist BO; Hoffman BM; Hedlund J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):671-5. PubMed ID: 8894578
[TBL] [Abstract][Full Text] [Related]
6. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
7. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
[TBL] [Abstract][Full Text] [Related]
8. Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae.
Calvo A; Giménez MJ; Alou L; Gómez-Lus ML; Aguilar L; Prieto J
Int J Antimicrob Agents; 2002 Aug; 20(2):144-6. PubMed ID: 12297365
[No Abstract] [Full Text] [Related]
9. Synergistic activity of trovafloxacin and ceftriaxone or vancomycin against Streptococcus pneumoniae with various penicillin susceptibilities.
Nicolau DP; Tessier PR; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1998 Apr; 42(4):991-2. PubMed ID: 9559832
[No Abstract] [Full Text] [Related]
10. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci.
Pankuch GA; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1995 Jan; 35(1):230-2. PubMed ID: 7768776
[No Abstract] [Full Text] [Related]
11. In vitro activities of five fluoroquinolone compounds against strains of Streptococcus pneumoniae with resistance to other antimicrobial agents.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 1996 Oct; 40(10):2431-3. PubMed ID: 8891160
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.
Bédos JP; Rieux V; Bauchet J; Muffat-Joly M; Carbon C; Azoulay-Dupuis E
Antimicrob Agents Chemother; 1998 Apr; 42(4):862-7. PubMed ID: 9559797
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Waites K; Brookings E; Nix S; Robinson A; Gray B; Swiatlo E
Int J Antimicrob Agents; 1998 Feb; 9(4):215-8. PubMed ID: 9573490
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of trovafloxacin (CP-99,219).
Morrissey I
J Antimicrob Chemother; 1996 Dec; 38(6):1061-6. PubMed ID: 9023654
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of penicillin-susceptible and -resistant pneumococci to CFC-222, a new fluoroquinolone.
Kim JH; Kang JA; Lee Y; Lee KH; Lee JH; Choi EC; Kim BK
J Antimicrob Chemother; 1998 Oct; 42(4):527-30. PubMed ID: 9818754
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of trovafloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in a murine sepsis model.
Lacy MK; Nicolau DP; Banevicius MA; Nightingale CH; Quintiliani R
J Antimicrob Chemother; 1999 Oct; 44(4):477-81. PubMed ID: 10588309
[TBL] [Abstract][Full Text] [Related]
19. Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
Kelly LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):707-9. PubMed ID: 10382894
[TBL] [Abstract][Full Text] [Related]
20. In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
Rodríguez JC; Llinares F; Royo G
Chemotherapy; 2001; 47(1):39-42. PubMed ID: 11125231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
